Crrelation of serum uric acid level with new emerging cardiovascular disease and diabeticnephropathy
-
摘要:
目的 探讨Ⅱ型糖尿病患者血尿酸水平与新发心血管疾病及糖尿病肾病的相关性。 方法 筛选西安市中心医院2014年11月~2016年11月280例糖尿病患者,以血尿酸水平为基准分为高尿酸组和正常尿酸组,各140例,检测两组患者心血管相关指标和肾损害指标,评价血尿酸水平与新发心血管疾病及糖尿病肾病的关系。 结果 高尿酸组患者的颈动脉内-中膜厚度、尿白蛋白/肌酐比值及甘三油酯高于正常尿酸组,差异有统计学意义(P<0.01);高尿酸组高血压、冠状动脉粥样硬化及糖尿病肾病的发生率高于正常尿酸组(P<0.05);高尿酸组冠状动脉粥样硬化和糖尿病肾病的发生时间分别为12.58±2.36月和11.75±1.96月,短于正常尿酸组(P<0.05);多元回归分析显示血尿酸水平是颈动脉内-中膜厚度、尿白蛋白/肌酐比值的主要影响因素。 结论 Ⅱ型糖尿病患者血尿酸水平与新发心血管疾病及糖尿病肾病呈正相关,随着血尿酸水平升高新发心血管疾病及糖尿病肾病的概率更高、发病时间更早。 Abstract:Objective To explore the relationship between serum uric acid level with new emerging cardiovascular disease and diabetic nephropathy in patients with type II diabetes. Methods A total of 280 patients with type II diabetic in xi’an central hospital from November 2014 to November 2016 were chosed as subject. Accrording to the level of serum uric acid, patients were divide into hyperuricemia group and normal uric acid group, with 140 cases in each group. Cardiovascular and renal damage indexes were detected in two groups, which were used to evaluate the relationship between serum uric acid level with newly emerging cardiovascular disease and diabetic nephropathy. Results The carotid artery medial thickness (IMT), urinary albumin/creatinine ratio (ACR) and the three oil ester (TG) in hyperuricemia group were significantly higher than those in normal uric acid group (P<0.01). The morbidity and occurrence time of cardiovascular disease and diabetic nephropathy in 2 groups showed significant differences (P<0.05). Multiple regression analysis showed that serum uric acid level was the main influence factor of IMT and ACR. Conclusion The relationship between serum uric acid level with new emerging cardiovascular disease and diabetic nephropathy was positive. Wish a rising of serum uric acid level, the morbidity of new emerging cardiovascular disease and diabetic nephropathy is higher and the occurrence time is earlier. -
表 1 高尿酸组与正常尿酸组各项检测结果分析(n=140,
$\, \overline{{x}}{{±}}{{s}}$ )指标 高尿酸组 正常尿酸组 t P IMT(mm) 1.12±0.36 0.84±0.27 3.584 0.001 BMI(kg/m2) 27.93±3.53 25.28±1.69 2.415 0.023 SBP(mmHg) 143.25±12.34 134.41±9.76 2.195 0.036 DBP(mmHg) 92.64±10.82 81.72±8.39 2.858 0.010 BUN(mmol/L) 9.33±6.76 6.41±2.27 2.413 0.018 Cr(μmol/L) 140.82±127.76 83.97±76.94 2.291 0.025 ACR(mg/mmol) 598.72±283.20 29.34±12.11 4.388 0.000 UAER(μg/min) 677.31±112.7 27.34±7.49 2.432 0.039 Cys-C(mg/L) 1.75±0.91 1.09±0.48 2.608 0.021 HbA1c(%) 11.35±3.21 11.28±2.99 0.08 0.936 FPG(mmol/L) 10.36±7.74 9.58±4.11 0.444 0.658 TC(mmol/L) 4.73±1.44 4.48±1.23 0.803 0.425 TG(mmol/L) 2.59±1.56 1.69±1.17 2.767 0.007 LDL-c(mmol/L) 2.75±1.17 2.74±1.02 0.041 0.967 HDL-c(mmol/L) 1.12±0.31 1.28±0.42 0.078 0.896 病程(年) 10.93±3.97 5.76±2.31 2.454 0.032 IMT: 颈动脉内-中膜厚度; BMI: 体质量指数; SBP: 收缩压; DBP: 舒张压; BUN: 尿素氮; Cr: 肌酐; ACR: 尿白蛋白/肌酐比值; UAER: 尿白蛋白排泄率; Cys-C: 血清胱抑素C; HbA1c: 糖化血糖蛋白; FPG: 空腹血糖; TC: 总胆固醇; TG: 甘三油酯; LDL-c: 度脂蛋白胆固醇; HDL-c: 高密度脂蛋白胆固醇. 表 2 两组患者心血管疾病与糖尿病肾病发生率及发生时间
高血压 动脉粥样硬化 糖尿病性肾病 发生率(n,%) 发生时间(月) 发生率(n,%) 发生时间(月) 发生率(n,%) 发生时间(月) 高尿酸组 58(41.43) 17.93±3.44 57(40.71) 12.58±2.36 89(63.57) 11.75±1.96 正常尿酸组 41(29.29) 32.58±2.88 34(24.29) 25.67±3.22 46(32.86) 20.66±3.03 χ2 4.516 5.829 8.612 11.557 26.448 4.997 P <0.05 <0.05 <0.01 <0.01 <0.01 <0.05 -
[1] 中华医学会糖尿病学分会. 中国Ⅱ型糖尿病防治指南(2010年版) [J]. 中国糖尿病杂志, 2012, 1(11): 1227-45. http://d.wanfangdata.com.cn/Periodical/zgtnbzz201201026 [2] 林立建, 谢良地. 血尿酸水平与高血压左心室肥厚的关系[J]. 中华高血压杂志, 2013, 21(8): 736-40. [3] 单二伟, 吴长威. 血清同型半胱氨酸和血尿酸水平对冠状动脉粥样硬化的影响[J]. 中国实用医药, 2014, 9(9): 122-3. http://d.wanfangdata.com.cn/Periodical/zgsyyy201409091 [4] 中国医师协会心血管内科医师分会, 中国医师协会循证医学专业委员会. 无症状高尿酸血症合并心血管疾病诊治建议中国专家共识[J]. 中国医学前沿杂志:电子版, 2010, 2(3): 49-55. http://d.wanfangdata.com.cn/Periodical/zgqkyx201011001 [5] Macisaac RJ, Ekinci EI, Jerums G. Markers of and risk factors for the development and progression of diabetic kidney disease[J]. Am J Kidney Dis, 2014, 63(Suppl 2): S39-62. [6] 葛均波, 徐永健, 梅长林, 等. 内科学[M]. 8版. 北京: 人民卫生出版社, 2014: 738-9. [7] Huang G, Xu JB, Zhang TJ, et al. Hyperuricemia is associated with cardiovascular diseases clustering among very elderly women-a community based study in Chengdu,China[J]. Sci Rep, 2017, 7(1): 996-9. doi: 10.1038/s41598-017-01042-6 [8] 胡云辉, 马依彤, 付真彦, 等. 颈动脉内-中膜厚度与冠状动脉粥样硬化性心脏病相关性研究[J]. 临床心血管病杂志, 2009, 25(7): 532-5. http://d.wanfangdata.com.cn/Periodical/lcxxgbzz200907016 [9] Liu C, Zhen Y, Zhao Q, et al. Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance[J]. Can J Physiol Pharmacol, 2016, 94(7): 797-800. doi: 10.1139/cjpp-2015-0490 [10] Lu WJ, Xu YZ, Shao XN, et al. Uric acid produces an inflammatory response through activation of NF-kappa B in the hypothalamus: implications for the pathogenesis of metabolic disorders[J]. Sci Rep, 2015, 5(12): 12144-8. [11] 裘丽红, 李武艳, 李晓娜, 等. 2型糖尿病合并急性缺血性脑血管病患者颈动脉斑块稳定性及相关因素分析[J].中国实用神经疾病杂志, 2013, 16(8): 27-31. http://d.wanfangdata.com.cn/Periodical/hnsysjjbzz201308013 [12] Marshall SJ. Peptic ulcer bleeding:an expedition of 20 years from 1989-2009[J]. J Gastroenterol Hepatol, 2010, 25(2): 229-31. doi: 10.1111/jgh.2010.25.issue-2 [13] 曹晏日方, 蔡危威,张丽莉.新诊断2型糖尿病患者微量白蛋白尿的患病率及危险因素分析[J]. 实用临床医药杂志, 2012, 16(7): 104-6. http://d.wanfangdata.com.cn/Periodical/jslcyxzz201207036 [14] Xiao J, Zhang XL, Fu C, et al. Soluble uric acid increases NALP3 inflammasome and interleukin-1β expression in human primary renal proximal tubule epithelial cells through the Toll-like receptor 4-mediated pathway[J]. Int J Mol Med, 2015, 35(5): 1347-54. doi: 10.3892/ijmm.2015.2148 [15] Fouad M, Fathy H, Zidan A. Serum uric acid and its association with hypertension,early nephropathy and chronic kidney disease in type 2 diabetic patients[J]. J Bras Nefrol, 2016, 38(4): 403-10. [16] 张丽.2 型糖尿病患者血尿酸水平变化的临床观察与检验价值[J].中国医学工程, 2016, 24(3): 123-4. [17] Gersch C, Palii SP, Kim KM, et al. Inactivation of nitric oxide by uric acid[J]. Nucleic Acids, 2008, 27(8): 967-78. doi: 10.1080/15257770802257952 [18] Yang Z, Xiaohua W, Lei J, et al. Uric acid increases fibronectin synthesis through upregulation of lysyl oxidase expression in rat renal tubular epithelial cells[J]. Am J Physiol Renal Physiol, 2010, 299(2): F336-46. doi: 10.1152/ajprenal.00053.2010 [19] Lytvyn Y, Perkins B, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes[J]. Can J Diabetes, 2015, 39(3): 239-46. doi: 10.1016/j.jcjd.2014.10.013 [20] Lanaspa MA, lshimoto T, Cicerehi C, et al. Endogenous fructose production and fruetokinase activation mediate renal injury in diabetic nephrepathy[J]. J Am Soc Nephml, 2014, 25(11): 2526-38. doi: 10.1681/ASN.2013080901
计量
- 文章访问数: 549
- HTML全文浏览量: 224
- PDF下载量: 2
- 被引次数: 0